| For: | Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S, Gullapalli N. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J Cardiol 2020; 12(11): 584-598 [PMID: 33312443 DOI: 10.4330/wjc.v12.i11.584] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v12/i11/584.htm |
| Number | Citing Articles |
| 1 |
Ja-Young Han, Young-Eun Seo, Jae-Hee Kwon, Jae Hyun Kim, Myeong Gyu Kim. Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database. Journal of Clinical Medicine 2024; 13(5) doi: 10.3390/jcm13051218
|
| 2 |
Dorte Lisbet Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, Inna Markovna Chen, Joerg Herrmann. Immune Checkpoint Inhibitor–Induced Cardiotoxicity. JAMA Oncology 2024; 10(10) doi: 10.1001/jamaoncol.2024.3065
|
| 3 |
Giuseppe Panuccio, Pierpaolo Correale, Maria d’Apolito, Luciano Mutti, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Demetrio Labate, Sebastiano Macheda, Nicole Carabetta, Youssef S. Abdelwahed, Ulf Landmesser, Pierfrancesco Tassone, Pierosandro Tagliaferri, Salvatore De Rosa, Daniele Torella. Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients. Basic Research in Cardiology 2024; 120(1) doi: 10.1007/s00395-024-01077-7
|
| 4 |
Yiran Rong, John P. Bentley, Kaustuv Bhattacharya, Yi Yang, Yunhee Chang, Sally Earl, Sujith Ramachandran. Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer. Cancer Medicine 2024; 13(1) doi: 10.1002/cam4.6879
|
| 5 |
Kong Vang, Jennifer Panich, Connie Folz, Hiral Patel, Nikhila Aimalla, Yuanli Lei, Thane Drier, Paige Hergenrother, Somto Nwaedozie, Chady A Leon. Evaluating patients on immune checkpoint inhibitors for cardiac adverse events: The EPICC study. Journal of Oncology Pharmacy Practice 2025; doi: 10.1177/10781552251349459
|
| 6 |
Chun-Ka Wong, Tsun-Ho Lam, Song-Yan Liao, Yee-Man Lau, Hung-Fat Tse, Benjamin Y. F. So. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. Biomedicines 2023; 11(1) doi: 10.3390/biomedicines11010107
|
| 7 |
Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. Journal for ImmunoTherapy of Cancer 2021; 9(10) doi: 10.1136/jitc-2021-002545
|
| 8 |
Chin-Chin Ho, Shang-Liang Wu, Han-Yi Tsai, Yu-Wen Hu, Yuh-Lih Chang. A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. Journal of the Chinese Medical Association 2023; 86(5) doi: 10.1097/JCMA.0000000000000910
|
| 9 |
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico Van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals 2023; 16(4) doi: 10.3390/ph16040625
|
| 10 |
Umut Selamet, Rebecca S. Ahdoot, Reed Salasnek, Lama Abdelnour, Ramy M. Hanna. Onconephrology: mitigation of renal injury in chemotherapy administration. Current Opinion in Nephrology & Hypertension 2024; 33(2) doi: 10.1097/MNH.0000000000000960
|
| 11 |
Angelica Toro Cora, Arvind Singh Bhati, Amdadul Huque, Imran Ansari, Baldeep Singh, Rohan Sethi, Daniel Y. Li, Qinkun Zhang, Alok Pant, Sindhu Priya Devarashetty, Hind Lal, Sultan Tousif. Myeloid-derived immunosuppressive PD-1/PD-L1 signaling is essential to maintain adult heart homeostasis. American Journal of Physiology-Heart and Circulatory Physiology 2026; 331(1) doi: 10.1152/ajpheart.00017.2026
|
| 12 |
Mandana Chitsazan, Ahmad Amin, Luisa Ladel, Alyza Baig, Mitra Chitsazan. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2023; 22(3) doi: 10.1097/HPC.0000000000000327
|
| 13 |
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, Emily Wang, Efstratios Koutroumpakis, Salil Kumar, Shaden Khalaf, Hyeon-Ju Ali, Anita Deswal, Nicolas L. Palaskas. Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge. The Journal of Cardiovascular Aging 2025; 5(1) doi: 10.20517/jca.2024.13
|
| 14 |
Sarah E. Mudra, Danny L. Rayes, Ankit Agrawal, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Kazi A. Kalam, Charalompos Charalampous, Mary Schleicher, Muhammad Majid, Alvena Syed, Abdullah Yesilyaprak, Allan L. Klein. Immune checkpoint inhibitors and pericardial disease: a systematic review. Cardio-Oncology 2024; 10(1) doi: 10.1186/s40959-024-00234-0
|
| 15 |
Tzu-Fei Wang, Alok A. Khorana, Marc Carrier. Thrombotic Complications Associated with Immune Checkpoint Inhibitors. Cancers 2021; 13(18) doi: 10.3390/cancers13184606
|
| 16 |
Chiara Pozzessere, Bianca Mazini, Patrick Omoumi, Mario Jreige, Leslie Noirez, Antonia Digklia, François Fasquelle, Christine Sempoux, Clarisse Dromain. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review. Cancers 2024; 16(14) doi: 10.3390/cancers16142585
|
| 17 |
Virginia S. Hahn, Kathleen W. Zhang, Lova Sun, Vivek Narayan, Daniel J. Lenihan, Bonnie Ky. Heart Failure With Targeted Cancer Therapies. Circulation Research 2021; 128(10) doi: 10.1161/CIRCRESAHA.121.318223
|
| 18 |
Josep Sabaté-Ortega, Eduard Teixidor-Vilà, Èlia Sais, Alejandro Hernandez-Martínez, Claudia Montañés-Ferrer, Núria Coma, Emma Polonio-Alcalá, Victor Pineda, Joaquim Bosch-Barrera. Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1528950
|
| 19 |
Omoruyi Credit Irabor, Nicolas Nelson, Yash Shah, Muneeb Khan Niazi, Spencer Poiset, Eugene Storozynsky, Dinender K. Singla, Douglas Craig Hooper, Bo Lu. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.940127
|
| 20 |
Jing Wu, Tingting Ni, Rong Deng, Yan Li, Qin Zhong, Fei Tang, Qi Zhang, Chunju Fang, Yingbo Xue, Yan Zha, Yu Zhang. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1065510
|
| 21 |
Zilong Luo, Han Zhang, Junjie Zong, Jun Hu, Pinyan Huang, Yuqing Niu, Cheng Zhou, Song Wang, Dan Zhang. The role of the PD-1/PD-L1 immune checkpoint pathway in myocardial infarction: a review from pathophysiological mechanisms to therapeutic strategies. Frontiers in Cardiovascular Medicine 2025; 12 doi: 10.3389/fcvm.2025.1691863
|
| 22 |
Masayoshi Oikawa, Takafumi Ishida, Yasuchika Takeishi. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. Journal of Cardiology 2023; 81(3) doi: 10.1016/j.jjcc.2022.04.006
|
| 23 |
Walid Shalata, Rachel Steckbeck, Amjad Abu Salman, Omar Abu Saleh, Ashraf Abu Jama, Zoé Gabrielle Attal, Sondos Shalata, Hilmi Alnsasra, Alexander Yakobson. Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. Medicina 2024; 60(2) doi: 10.3390/medicina60020224
|
| 24 |
Ahmad Naser, Ahmed Ashraf Morgan, Lili Zhang. Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy. Journal of Cardiovascular Development and Disease 2026; 13(8) doi: 10.3390/jcdd13080385
|
| 25 |
Jefferson Ko, Thomas Wardill, Sean Tan, Satish Ramkumar, Diego Araiza-Garaygordobil, Albert Galyavich, Cuiro Santoro, Diego Araiza-Garaygordobil, Maria Isabel Gonzalez del Hoyo. Immunotherapy-mediated myocarditis and concurrent vasospastic angina in a patient with established ischaemic heart disease: a case report. European Heart Journal - Case Reports 2024; 8(12) doi: 10.1093/ehjcr/ytae620
|
| 26 |
Liga Vidusa, Oskars Kalejs, Aija Maca-Kaleja, Ilze Strumfa. Role of Endomyocardial Biopsy in Diagnostics of Myocarditis. Diagnostics 2022; 12(9) doi: 10.3390/diagnostics12092104
|
| 27 |
Juan I. Ruiz, Bo Zhao, Nicolas Palaskas, Anita Deswal, Hui Zhao, Jennifer McQuade, Maria E. Suarez-Almazor. Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology 2025; 8(2) doi: 10.36401/JIPO-24-31
|
| 28 |
Alessandro Inno, Andrea Chiampan, Laura Lanzoni, Matteo Verzè, Giulio Molon, Stefania Gori. Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients. Frontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.652186
|
| 29 |
Feifei Wang, Qi Wei, Xinan Wu. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.986357
|
| 30 |
Bingxun Li, Mingjie Lin, Lin Wu. Drug-induced AF: Arrhythmogenic Mechanisms and Management Strategies. Arrhythmia & Electrophysiology Review 2024; 13 doi: 10.15420/aer.2023.24
|
| 31 |
Junya Yamaguchi, Tetsuji Morishita, Hiroyasu Uzui, Kanae Hasegawa, Hiroyuki Ikeda, Hiroshi Tada. Utility of echocardiographic parameters in predicting cardiac immune-related adverse events in Japanese patients undergoing immune checkpoint inhibitor therapy. Journal of Echocardiography 2026; 24(1) doi: 10.1007/s12574-025-00698-8
|
| 32 |
Amalia Papanikolopoulou, Helena Michalopoulou, Konstantinos G Kyriakoulis, Polyxeni Alexiou, Nikolaos Syrigos, John Vathiotis, Costas Thomopoulos, Andriani Charpidou. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data. Cureus 2025; doi: 10.7759/cureus.87049
|
| 33 |
Honglin Li, Deting Han, Lei Zhang, Xiaoteng Feng, Huijie Li, Feiran Yang, Lucheng Song, Xiurong Li. Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review. Immunotherapy 2022; 14(7) doi: 10.2217/imt-2021-0223
|
| 34 |
Nathaniel E. Davis, Narut Prasitlumkum, Nicholas Y. Tan. Atrial Fibrillation and Cancer—Epidemiology, Mechanisms, and Management. Journal of Clinical Medicine 2024; 13(24) doi: 10.3390/jcm13247753
|
| 35 |
Udhayvir S. Grewal, Stefano H. Byer, Sidharth Mahajan, Aakash R. Sheth, Kavitha Beedupalli, Michael G. Fradley, Eric H. Yang, Andrea M. Russo, Aarti Asnani, Paari Dominic. Atrial Fibrillation and Cancer. JACC: Clinical Electrophysiology 2026; 12(1) doi: 10.1016/j.jacep.2025.09.044
|
| 36 |
Diana Larisa Mocan-Hognogi, Sebastian Trancǎ, Anca Daniela Farcaş, Radu Florin Mocan-Hognogi, Andrada Viorica Pârvu, Anca Simona Bojan. Immune Checkpoint Inhibitors and the Heart. Frontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.726426
|
| 37 |
Zhuo Ma, Ximu Sun, Yi Zhang, Hao Li, Dan Sun, Zhuoling An, Yuhui Zhang. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials. Thrombosis and Haemostasis 2022; 122(10) doi: 10.1055/s-0042-1749185
|
| 38 |
Jiayi Chen, Shuang Liu, Zheng Ruan, Kankan Wang, Xiaodong Xi, Jianhua Mao. Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk. Blood Reviews 2024; 67 doi: 10.1016/j.blre.2024.101220
|
| 39 |
Lakshya Seth, Nickolas Stabellini, Shawn Doss, Vraj Patel, Viraj Shah, Gregory Lip, Susan Dent, Michael G. Fradley, Lars Køber, Avirup Guha. Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions. Journal of Thrombosis and Thrombolysis 2025; 58(8) doi: 10.1007/s11239-025-03104-3
|
| 40 |
Giselle Alexandra Suero-Abreu, Markella V. Zanni, Tomas G. Neilan. Atherosclerosis With Immune Checkpoint Inhibitor Therapy. JACC: CardioOncology 2022; 4(5) doi: 10.1016/j.jaccao.2022.11.011
|
| 41 |
Younan Samuel, Aswin Babu, Foteini Karagkouni, Ayden Ismail, Sunyoung Choi, Stergios Boussios. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine. Current Issues in Molecular Biology 2023; 45(10) doi: 10.3390/cimb45100526
|
| 42 |
Garrett Jensen, Xinjie Wang, Jacob Kuempel, Nicolas Palaskas, Zhishi Chen, Wei Yu, Yanping Chen, Haseeb Mohammad, Weijia Luo, Jiang Chang. Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review. American Journal of Physiology-Heart and Circulatory Physiology 2025; 328(4) doi: 10.1152/ajpheart.00687.2024
|
| 43 |
Michał Gawlik, Jakub Michal Zimodro, Aleksandra Gąsecka, Krzysztof J. Filipiak, Sebastian Szmit. Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines. Current Oncology Reports 2023; 25(10) doi: 10.1007/s11912-023-01445-x
|
| 44 |
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh-Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil. Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre Analysis. ESC Heart Failure 2025; 12(2) doi: 10.1002/ehf2.15131
|
| 45 |
Clemence Rigaux, Dimitri Arangalage, Karissa Adkins, Stephane Illiano. Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients. Lung Cancer 2026; 218 doi: 10.1016/j.lungcan.2026.109499
|
| 46 |
Andrea Camerini, Alessandro Inno, Maria Laura Canale, Stefano Oliva, Andrea Tedeschi, Alessandra Greco, Marzia De Biasio, Nicola Maurea, Irma Bisceglia, Luigi Tarantini, Giuseppina Gallucci, Carmine Riccio, Giovanna Geraci, Claudio Bilato, Alessandro Navazio, Attilio Iacovoni, Furio Colivicchi, Massimo Grimaldi, Fabrizio Oliva. Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore. International Journal of Molecular Sciences 2025; 26(18) doi: 10.3390/ijms26189100
|
| 47 |
Rhys Gray, Charlotte Manisty, Richard Cheng, Amardeep Dastidar, Mamas Mamas, Arjun Ghosh. Immune checkpoint inhibitors: Unravelling atherosclerotic cardiovascular risk. Atherosclerosis 2025; 403 doi: 10.1016/j.atherosclerosis.2025.119147
|